10 December 2019

ImmunOs Therapeutics AG, a Swiss biotechnology company and leading developer of a next generation innate immunity focused immunotherapy platform for cancer, announced today the closing of a Series A financing of CHF 15 million. The financing will be used to complete the first-in-human trials with the company’s lead agent, iosH2, a potential new cancer treatment for both solid and liquid tumors. The funding will also be used to broaden the company’s novel immunotherapy iosH platform by advancing additional preclinical programs focusing on both cancer and auto-immunity.

VISCHER acted as counsel to ImmunOs. The team was led by Christian Wyss (Partner) and supported by Luzius Zumstein (Associate), both Corporate.

Press release

Categories: Corporate and Commercial, Life Sciences, Pharma, Biotech, Mergers & Acquisitions, Private Equity & Venture Capital, Startup Desk

You are currently offline. Some pages or content may fail to load.